Anton Lindqvist

Oldtech, Inc. was engaged in developing treatments for conditions that affect the back of the eye, including age related macular degeneration (AMD) and diabetic macular edema (DME). The company was headquartered in New York.

McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY.

Vasakronan AB operates as a real estate development company. The company owns, develops, and manages commercial properties. Its properties are situated in clusters and offer supplementary services to the tenants. The firm's business activities also include office and retail leasing, and green leases and green offices development. The company was founded in 1955 and is headquartered in Stockholm, Sweden.

Industrifonden is a Venture Capital firm, a subsidiary of Government of Sweden founded in 1979. The firm is headquartered in Stockholm.

Imsys Technologies AB operates as a fabless semiconductor company, that designs and supplies networked control solutions to OEMs in the market of embedded control, telematics, automation, and the Internet of Things. The firm supplies processors, modules and tools for embedded applications. Its products include microprocessors; SNAP Velox, SNAP FX, and SNAP Classic modules; and SNAP Velox and SNAP Classic kits, and trace adapters. The company was founded by Stefan Blixt and Roger Sundman in 1981 and is headquartered in Upplands Vasby, Sweden.

Newron Sweden AB is a biopharmaceutical company engaged in the development of novel therapies for the treatment of disorders of the central nervous systems. The company was founded by Jonas Cristopher Frisen and Ann Marie Janson in 1998 and is headquartered in Stockholm, Sweden.

American Diabetes Association provides diabetes related medical services. It funds research, publishes scientific findings, provides information and other services to people with diabetes, their families, health professionals and the public. The company was founded in 1940 and is headquartered in Alexandria, VA.

JDRF International is a leader in setting the agenda for diabetes research worldwide, and is the largest charitable funder of and advocate for type 1 diabetes research. JDRF find a cure for diabetes and its complications through the support of research. Type 1 diabetes is an autoimmune disease that strikes children and adults suddenly, and can be fatal. Until a cure is found, people with type 1 diabetes have to test their blood sugar and give themselves insulin injections multiple times or use a pump each day, every day of their lives. And even with that intensive care, insulin is not a cure for diabetes, nor does it prevent its potential complications, which may include kidney failure, blindness, heart disease, stroke, and amputation. It was founded in 1970 and is headquartered in New York, NY.

Atlas Antibodies AB develops antibodies and reagents for Mass Spectrometry (MS)-based quantitative proteomics. Its project Human Protein Atlas aim to present an expression map of the complete human proteome. It offers characterized antibodies to various protein coding human genes; Triple A Polyclonals that are research grade rabbit polyclonal antibodies; and mouse monoclonal antibodies to selected proteins, as a complement to rabbit polyclonal antibodies. Its antibodies are used to study human proteins, for basic research purposes and clinical research in various disease areas, such as cancer and neurological brain diseases. The company was founded by Jan Fredrik Pontén, Karin Marianne Hansson, Henrik Wernérus, and Carl Erik Mathias Uhlén in 2006 and is headquartered in Stockholm, Sweden.

Joslin Diabetes Center, Inc. is a non-profit organization, which engages in the development of pharmaceuticals for diabetes. It provides adult care, pediatric care, eye care, and education programs and classes. The company was founded by Elliott P. Joslin in 1893 and is headquartered in Boston, MA.

Cogmed develops and markets software-based working memory training products for improved attention. The company's products are a unique combination of breakthrough research, original software design and effective support methodology. Cogmed is a privately held company founded in Stockholm, Sweden in 2001. The founders are neuroscientists at the Karolinska Institute in Stockholm and game developers. The firm's main markets are the United States and Sweden. In 2006 Cogmed established its U.S. offices in Naperville and Illinois. Cogmed works with practices across the United States and Canada. It also has partners in Japan, in several European countries, and around the world. Cogmed is involved in evidence-based cognitive training. The firm has research results, scientifically validated, showing that Cogmed training provides substantial and lasting improvements in attention, for people with poor working memory, in all age groups. That makes Cogmed's products the best-validated products on the market.

Umecrine AB provides pharmaceuticals against mental and physical symptoms. It develops antagonists to reduce symptoms and conditions caused by endogenous sex and stress hormones on the brain. The company was founded by Carl Torbjörn Bäckström in 2000 and is headquartered in Umea, Sweden.

Obstetrics & Gynecology, Inc. engages in providing obstetrics and gynecology (ObGyn) and women's health services. The company is headquartered in St. Louis, MO.

Umecrine Cognition AB develops pharmaceuticals against neurological disorders in the central nervous system. The firm focuses on the development and commercialization of novel therapeutics to treat Hepatic Encephalopathy in patients with liver disease. The company was founded by Torbjörn Bäckström in 2006 and is headquartered in Solna, Sweden.

Part of InDex Pharmaceuticals Holding AB, InDex Diagnostics AB manufactures pharmaceutical products. The company is based in Solna, Sweden. Peter Hakim Zerhouni has been the CEO of the Swedish company since 2015.

Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland.

InDex Pharmaceuticals AB is a pharmaceutical development company, which engages in the research, development of technology, and commercialization of scientific discoveries focusing on immunological diseases. It also offers the drug candidate cobitolimod and DiBiCol diagnostic kit. The company was founded was founded on December 14, 2015 and is headquartered in Solna, Sweden.

Hoa’s Tool Shop AB develops a mobile application for therapists treating depression. Its web and mobile applications contributes in human psychology interpretation. The company was founded by Kien Hoa Ly, Chacón Chacón Jordi, Andreas Amsenius, and John Markus Airaksinen on February 12, 2011 and is headquartered in Stockholm, Sweden.

Aadi Subsidiary, Inc. engages in biopharmaceutical company. Its therapeutic programs include pulmonary arterial hypertension, pediatric solid tumors, solid tumors with mTOR activation and mitochondrial disease. The company was founded by Neil Desai and is headquartered in Pacific Palisades, CA.

Reimersholmes Kooperativa Daghem Ekonomiska Förening operates a preschool.

Elypta AB develops the first metabolism-based liquid biopsy platform enabling early detection and closer follow-up of cancer. The company was founded by Francesco Gatto and Jens Nielsen in 2017 and is headquartered in Stockholm, Sweden.

Mertiva Diagnostics AB manufactures diagnostic devices. The private company is based in Stockholm, Sweden.

AnaCardio AB is a clinical stage biopharmaceutical company based in Stockholm, Sweden. AnaCardio develops drugs targeting a novel mechanism that improves cardiac contractility to treat heart failure, a progressive cardiac syndrome affecting more than six million individuals in the US and nearly 100 million worldwide. The Swedish company's unique solution is based on the ghrelin signaling pathway, intended to increase contractility without causing adverse tachycardia, arrhythmia, ischemia, or hypotension. The company was founded by Lars Lund and is currently led by CEO Patrik Strömberg since 2021.